[促性腺激素释放激素激动剂（布舍瑞林）短期给药在体外受精中的有益作用]

[The beneficial effects of short-term administration of a LHRH agonist (buserelin) in in vitro fertilization].

作者信息

Loumaye E, de Cooman S, Psalti I, Schrurs B, Adam T, Depreester S, Thomas K

机构信息

Services d'Obstétrique et de Gynécologie, Cliniques Universitaires Saint-Luc, Université de Louvain, Bruxelles.

出版信息

J Gynecol Obstet Biol Reprod (Paris). 1988;17(8):1081-7.

PMID:3148649

Abstract

We have assessed the beneficial effects of administering a short course of an agonist of LHRH (Buserelin) in vitro fertilisation. 274 cycles were treated with CC-HMG, 159 were treated with HMG alone and 253 by Buserelin-HMG. These were compared retrospectively. The use of a short course of Buserelin lowered significantly the rate of failed treated cycles (7% instead of 19% when it was used with CC-HMG and 27% when used with HMG). This made it possible to administer hCG in all cases in the programme (100% as against 69% and 89% respectively for CC-HMG and HMG without Buserelin), and increase significantly the number of oocytes that could be recovered and the number of embryos available for transfer. The overall number of pregnancies per cycle treated is significantly raised when Buserelin is used with HMG (20.4% as against 13.5% for CC-HMG and HMG). The number of pregnancies that progressed, on the other hand, was similar when the cycle was stimulated with HMG alone (10.6%) or with Buserelin-HMG (10.6%).

摘要

我们评估了在体外受精中给予短疗程促黄体生成素释放激素（LHRH）激动剂（布舍瑞林）的有益效果。274个周期采用氯米芬-人绝经期促性腺激素（CC-HMG）治疗，159个周期仅采用HMG治疗，253个周期采用布舍瑞林-HMG治疗。对这些进行回顾性比较。使用短疗程布舍瑞林显著降低了治疗失败周期的发生率（与CC-HMG联合使用时为7%，而不是19%；与HMG联合使用时为27%）。这使得在该方案的所有病例中都能够给予人绒毛膜促性腺激素（hCG）（分别为100%，而不使用布舍瑞林的CC-HMG和HMG为69%和89%），并显著增加了可回收的卵母细胞数量和可用于移植的胚胎数量。当布舍瑞林与HMG联合使用时，每个治疗周期的妊娠总数显著增加（20.4%，而CC-HMG和HMG为13.5%）。另一方面，当单独使用HMG（10.6%）或布舍瑞林-HMG（10.6%）刺激周期时，进展的妊娠数量相似。